Sources: OpenEvidence, an AI search engine for doctors, raised $250M at a $15B valuation, up from $12B in January; it could be open to selling itself
Context & Ripple Effects
OpenEvidence’s funding arc moved from a $1 billion first outside round in February 2025 to a $12 billion financing in January 2026. The company has paired that capital trajectory with an ad-supported physician search product; it said in May that its service reached about 65% of U.S. physicians.
The reported $15 billion valuation arrives a day after [[a:1295469|OpenEvidence and Anthropic announced a physician-focused deployment in about 100 low- and middle-income countries]]. That combination makes distribution and clinical-user adoption central to the company’s valuation case, rather than model development alone.
First-order effects
- If the reported financing closes, OpenEvidence’s reference valuation rises from January’s $12 billion to $15 billion, giving it a higher-priced basis for future fundraising or any sale discussions.
- The reported openness to a sale puts OpenEvidence’s physician distribution, advertising business, and Anthropic partnership into sharper focus for prospective acquirers; a transaction is not confirmed.
Second-order effects
- OpenEvidence will face greater pressure to translate its claimed physician reach and previously reported annualized ad revenue into growth that supports the higher valuation.
- Anthropic’s international partnership becomes a more consequential distribution channel for OpenEvidence as the company seeks to demonstrate that its medical-search product can extend beyond its U.S. physician base.
Third-order effects
- If specialist AI products continue to command rising private valuations on the strength of professional distribution, clinical search may consolidate around platforms that combine trusted workflows, monetization, and model partnerships.
- The pattern shifts competitive advantage in vertical AI away from a general-purpose chatbot alone and toward control of high-frequency professional audiences.
The trend: Vertical AI companies are being valued increasingly on proprietary professional distribution and monetization, with model partnerships used to broaden reach.